Population-based studies have assessed the influence of common SNPs related to AF on the response to antiarrhythmic drug (AAD) therapies and showed that carriers of the variant allele at rs10033646 on chromosome 4q25 (Pitx2) responded favourably to the class I AAD (flecainide)[22–26]. Here, PITX2 is linked to atrial fibrillation.